New hope for Tough-to-Treat lung cancer: first patients test novel drug

NCT ID NCT06521554

Summary

This is the first study in people testing a new oral drug called NVL-330 for advanced lung cancer that has a specific genetic change called HER2. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the drug might help control the cancer in up to 200 participants whose cancer has progressed after other treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chris O'Brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, NSW 2050, Australia

    Contact

  • City of Hope - Lennar

    RECRUITING

    Irvine, California, 92618, United States

    Contact

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

    Contact

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-••••

  • Georgetown University Medical Center

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact

  • Henry Ford Cancer Center

    RECRUITING

    Detroit, Michigan, 48242, United States

    Contact

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center

    RECRUITING

    Baltimore, Maryland, 21224, United States

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

  • North Shore Health Hub

    RECRUITING

    Saint Leonards, New South Wales, 2065, Australia

    Contact

  • OSU Brain and Spine Hospital

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

  • Princess Margaret Cancer Center - University Health Network

    RECRUITING

    Toronto, Ontario, M5G 1L7, Canada

    Contact

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

  • Sarah Cannon Research Institute at HealthONE

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact

  • Sibley Memorial Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20016, United States

    Contact

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 94305, United States

    Contact

  • Sylvester Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • University of California, Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

Conditions

Explore the condition pages connected to this study.